The Department of Surgery has many faculty members who are involved in a wide variety of investigations to not only improve clinical healthcare but also to treat diseases that require surgical intervention.
The Cardiothoracic Research Program consists of over 20 studies and includes the entire CT faculty. CT surgeons are very active in participating in research trials and have been the top enrollers on numerous studies. Our research nurses have over 35 years combined acute clinical and research experience. They are available 24 hours/7 days a week to support after-hours activities. Continued dedication and communication make the CT Research Program the success it is today.
Since the appointment in 2009 of Dr. B. Mark Evers as Professor of Surgery and Director of The Markey Cancer Center, the General Surgery division has acquired four Molecular Research labs. The General Surgery Clinical Research Program is a comprehensive program that supports every aspect of clinical research conduct. The program assists investigators in protocol development and grant submissions for competitive clinical research grants. The program works in conjunction with pharmaceutical and device companies to conduct industry clinical trials. The Basic Science Research Program in the Division of General Surgery is in a well-equipped and staffed cellular and molecular laboratory with powerful collaborations and related core facilities. A full-time Laboratory Director with broad training and experience in cellular and molecular biology and immunology supports faculty investigators, residents and medical and undergraduate students in bench and translational projects.
The University of Kentucky Plastic Surgery research laboratory efforts are presently in the areas of wound healing including burns, breast cancer etiology, craniofacial growth, tendon repair, and microvascular surgery. The Division operates two basic research laboratories which also house our microsurgery-teaching laboratory.
The UK HealthCare Transplant Institute has an active clinical research program. Transplant team physicians are currently participating in numerous industry-sponsored multi-center as well as single and multi-center investigator-initiated trials. Current trials include investigations of different immunosuppression medication regimens using FDA approved drugs, as well as investigational compounds in liver and kidney transplants.
The research efforts of Dr. Natasha Kyprianou's lab focus on the identification of the molecular changes in the apoptotic cell death signaling contributing to the development and progression of human prostate cancer.